No Data
No Data
Virpax Pharmaceuticals to Present at 2024 BIO International Convention
Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
Maxim Group Downgrades Virpax Pharmaceuticals(VRPX.US) to Hold Rating
Maxim Group analyst Naz Rahman downgrades $Virpax Pharmaceuticals(VRPX.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 29.7% and a total average return of -11.5% ov
Maxim Group Downgrades Virpax Pharmaceuticals to Hold
Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals from Buy to Hold.
Virpax Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 — Maxim Group Downgrades Buy → Hold 06/09/2022 471.43% Maxim Group → $4 Initiates Coverage On
SINTX Technologies SINT Earnings; Virpax Pharmaceuticals VRPX Earnings
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble
Virpax Pharmaceuticals (VRPX) shares tumbled more than 65% in recent Wednesday trading after the company priced its public offering of slightly more than 1.6 million common shares and related warrants
No Data